EP2409969A1 — Pyrimidine urea derivatives as kinase inhibitors
Assigned to IRM LLC · Expires 2012-01-25 · 14y expired
What this patent protects
The invention relates to compounds of formula (IV*) wherein the substituents X 1 , R 1 , R 2 , R 3 , R 4 , H a , A and R 16 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical …
USPTO Abstract
The invention relates to compounds of formula (IV*) wherein the substituents X 1 , R 1 , R 2 , R 3 , R 4 , H a , A and R 16 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.